Investor FAQs

Futura Medical’s headquarters are based in Guildford, Surrey, UK. Please see our Location for further information.

Futura Medical plc is quoted on AIM and the ticker symbol is FUM.

Please see our Directors and biographies.

Please see our Financial Calendar.

Please register for our news alert service.

Online versions of our recent Annual Reports and results statements are available in the Investor Centre section of our website, and can be downloaded here. You can also request a hard copy of the company's annual report by emailing investor.relations@futuramedical.com.

The AGM usually takes place in June each year. Confirmed dates are listed in our Financial Calendar.

Please see details of our Analyst coverage here.

Please find the necessary contact details here.

Brighter IR is a provider we use to feed share price information to our website and to provide the news alert service which enables users who are registered with their service to receive alerts when regulatory news is released to the Futura website. Alma Strategic Communications are appointed to provide IR/PR services.

With the introduction of GDPR, Brighter IR requires your permission to use your personal information to contact you and this is done via their registration.  Please note that once registered, you will begin to receive news alerts via email.  You do not need to log into the Brighter IR portal to access the press releases, they are available on our website through the automated feed.  The Brighter IR portal is to allow you to amend or delete the permissions you have given to them to access your personal information and to contact you via the alert service.

Futura Medical plc is quoted on AIM and the ticker symbol is FUM.

Futura Medical shares can be bought and sold through a stockbroker or share dealing service.

Please see our Shareholder Information page.

No, Futura currently does not pay a dividend.

You will need to complete a share transfer form, which can be obtained from the Registrars. The form should be fully completed and returned to them with your share certificate to arrange transfer of ownership.

You will need to contact the Registrars for this information.

For general enquires contact 0371 664 0300 (calls are charged at the standard geographical rate and may vary by provider, lines are open 9.00am-5.30pm Mon-Fri) (or +44 (0) 37 1664 0300 from outside the UK) between 09:00 and 17:30 on each business day.

www.eu.mpms.mufg.com

If you have changed your name or home address you should notify the Registrars in writing. Please quote your full name, the old and new addresses, and/or provide documentary evidence (such as a copy of your marriage certificate or change of name by deed poll), as applicable. You should also enclose your share certificate for amendment.

You should notify the Registrars. Restriction will then be placed on the missing share certificate in case of any attempted fraud. A letter of indemnity will be sent to you to sign. Once completed and returned to the Registrars a replacement certificate can be issued. There is a charge for this service. If the missing share certificate subsequently appears, you should return it to the Registrars to be cancelled.

Please contact the Registrar, who will be able to assist you.

Eroxon^® is the brand name used by a number of distributors whereas MED3000 was the codename used by Futura during the product development phase.  The use of Eroxon^® as a brand name may vary country to country dependent on a number of factors, such as regulatory approval and the local trademark situation which may be outside the control of Futura or the distributor.

Eroxon^®, our lead product was developed specifically for the treatment of erectile dysfunction (“ED”). Eroxon^® is a fast-acting topical treatment which has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market. 

The efficacy of Eroxon^® has been demonstrated in two Phase 3 trials in 300 men with mild, moderate, and severe ED, which investigated improvement in their erectile function compared with baseline. Our commercial partners have also independently conducted four “home-use” studies with over 600 users to validate the strength of the proposition. This has confirmed results that are aligned with the Eroxon® clinical efficacy data (>60% success rate) providing real world evidence.

Reported side effects of Eroxon^® in the trials were minimal: 3% of men reported a headache, significantly fewer than associated with the PDE5i’s,  1% of men reported a ‘localised burning sensation’ and 1.3% of partners reported a headache.

Eroxon^® is for use in men who experience ED. It should not be used by those who do not have problems with ED.

No, Eroxon^® is the first clinically proven topical therapy for erectile dysfunction that can be bought in the UK without the need for a prescription, and is available in many pharmacy and retail stores across the UK.

As well as being available without a doctor’s prescription (‘over the counter’), Eroxon^®, is also available on prescription in England and Wales for the treatment of erectile dysfunction since the 1st of March 2024.

Eroxon^® is also available online and in retailers across a number of countries in Europe and the rest of the world with further launches planned. For more information on the go-to-market progress of Eroxon^® click here and on the commercialisation of Eroxon^® click here.

Eroxon^® launched in April in the UK and was initially available on boots.com and in store. It is also now available in other pharmacies and retailers across the UK.

The definition of a medical device includes products which are used in the treatment of illness or disease but which do not achieve their principal intended action on the human body by pharmacological, immunological or metabolic means. Medical devices are subject to stringent regulations to establish safety and effectiveness.

Approval of Eroxon^® as a medical device clinically proven to treat erectile dysfunction has been granted in key markets around the world, including the USA and EU as well as a growing number of other countries.

Eroxon^® became available in the UK and in Belgium online and in store in April 2023.

Eroxon^® has since launched in the key European markets of France, Italy and Spain as well as other European markets, both online and in retail stores, supported by advertising and promotion.

Futura's breakthrough, topical gel formulation Eroxon^® is the first pan-European topical treatment for erectile dysfunction ("ED") available without the need of a doctor's prescription.

Eroxon^® is available to purchase online and in retail stores across a growing number of markets across the world.  Further details can be found online at www.eroxon.com.

Eroxon^® received US Food and Drug Administration (FDA) marketing authorisation as an OTC product on 9 June 2023 as a De Novo medical device.

In July 2023, Futura Medical announced that it had entered into a ground breaking licensing agreement with Haleon plc ("Haleon"), a world leading consumer healthcare Company for the rights to exclusively commercialise the Company's innovative topical, gel-based erectile dysfunction ("ED") treatment Eroxon^®, in the USA. Haleon is responsible for the launch and ongoing regulatory, development, marketing, and commercialisation of Eroxon^® in the USA.

Eroxon^® is now available to purchase from leading retailers in the USA following the launch in October 2024.

www.eroxon.us

Eroxon^® has been granted marketing authorisation in many countries across the world.

Futura has signed commercial deals across the world covering Europe, the USA, Central and South America and the Middle East. Launches commenced in 2023 and are continuing.

August 2021:  M8 Pharmaceuticals to commercialise Eroxon^® in Brazil and Mexico, which was expanded in November 2023 to a further fourteen countries covering the Central and South American region.

September 2021:  Labatec Pharma to commercialise Eroxon^® in the Gulf and Middle East Region.

May 2022: Cooper Consumer Health to commercialise Eroxon^® throughout the European Economic Area, United Kingdom and Switzerland. In January 2024 the agreement was extended to last another five years until January 2029.

In 2023, Futura signed or expanded the following commercial deals:

July 2023: Haleon to exclusively commercialise Eroxon^® in the USA.

November 2023: Futura expands partnership with M8 Pharmaceuticals.

October 2024: Haleon launches Eroxon^® in the USA.

For more detail on which countries Eroxon^® is approved in, which commercial partners cover which countries and where Eroxon^® has been launched, please refer to our interactive map on page 17 of the  2024 Annual Report .

All distribution will be handled by our appointed distribution partners and retailers. Eroxon^® addresses the significant and specific medical needs of men who suffer from erectile dysfunction and its use, where approved to be a treatment without the need for a doctor’s prescription, will require careful consideration by the patient in terms of self-diagnosis and use according to product label information.

At this time, we have not tested the product in patients who have undergone radical prostatectomy although the product has been shown to be effective in mild, moderate and severe ED of mixed causes.

If you have a medical condition other than erectile dysfunction you may need to speak to a doctor to discuss your condition to see if the product is suitable for you to use.

Eroxon^® is accompanied by a leaflet, containing warnings and precautions and recommending users have a check-up with their doctor as soon as possible within the first 6 months of using Eroxon^® to ensure that their erection problems are not caused by another serious health condition.

We have not conducted studies on Eroxon^® in combination with PDE5i’s. It is likely that a post-approval study will be needed to demonstrate synergy. We do not anticipate any safety issues in combining the two treatments.

We have a shelf life of 3 years.

It is currently being sold in the UK in Boots for £24.99 for 4 single use applications. Pricing may vary by country and commercial partner and is the responsibility of the commercial partner.

Eroxon® Intense is an additional treatment option for erectile dysfunction that is aimed at helping the cohort of men that may prefer a stronger sensation from Eroxon®.

We are expecting regulatory approval in the EU and USA by the end of 2025.

WSD4000 is a topical gel that is being specifically designed to treat symptoms of sexual dysfunction in women, providing improvements in sexual desire, arousal, lubrication, pain during intercourse, orgasm and overall sexual satisfaction. Currently, no regulatory approved topical treatment for sexual dysfunction in women is available over the counter.

We are unable to provide a firm date for when WSD4000 will become available. A further pre-submission meeting with the FDA has taken place, where good progress was made to clearly define the product’s indication for use, the potential claims, and how these should be proven during the clinical phase of development. Following the FDA meeting and the success of the study we are proceeding  with an Early Feasibility Study to be completed in the first half of 2026. This will enable the Group to consider refinements to the methodology in a population more representative of the target user and therefore hope to increase efficacy still further, as well as further inform on perceptions of the product. WSD4000 has the potential to be an effective breakthrough treatment for the common symptoms of sexual dysfunction in women and is a large and significant commercial opportunity in a market where there are very few treatments available to women .

Futura does use the services of a number of Key Opinion Leaders (KOLs) on an advisory basis which may result, at times, in financial payments being made.  These payments are in line with current market rates and also in accordance with the guidelines set out by the Prescription Medicines Code of Practice Authority (PMCPA), which states: “No gift, pecuniary advantage or benefit may be supplied, offered or promised to members of the health professions or to other relevant decision makers in connection with the promotion of medicines or as an inducement to prescribe, supply, administer, recommend, buy or sell any medicine.”

The maximum payment made by the Company was £7,200.

An initial UK patent was filed in December 2019 around Eroxon^®’s clinically significant and novel findings shown in our  clinical trials, followed by further supplementary UK filings to establish a priority date prior to a Patent Cooperation Treaty (“PCT”) and certain non-PCT patent applications in late 2020 as well as additional applications subsequently seeking to extend the depth of Futura’s intellectual property behind Eroxon^®.

The PCT currently has 153 contracting countries where the Company can seek patent protection claiming priority from an original application such as the UK.

On 2 October 2023, Futura announced that the European Patent Office granted a patent for Eroxon^®, providing protection to 2040. In all other key ED markets including the US, the Company is continuing to prosecute patent applications to provide wider patent protection and further options for patent filings to extend scope of protection is also progressing.